Protocol Ledger

NCT03266640 · Phase II · RECRUITING

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

Interventional Phase II clinical trial protocol NCT03266640 sponsored by New York Medical College in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-11-01 Enrollment: 20 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03266640
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)20 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03266640
Protocol FieldVerified Registry Value
NCT IdentifierNCT03266640
Consolidated Lead SponsorNew York Medical College
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment20 participants (ESTIMATED)
Registered Start Date2018-11-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI